Immunogenic oncolysis by tigilanol tiglate.

IF 6.5 2区医学 Q1 IMMUNOLOGY

Oncoimmunology Pub Date : 2024-05-27 eCollection Date: 2024-01-01 DOI:10.1080/2162402X.2024.2360230

Jonathan G Pol, Manuela Lizarralde-Guerrero, Guido Kroemer

引用次数: 0

Abstract

Tigilanol tiglate is an oncolytic small molecule that is undergoing clinical trials. A recent study revealed the capacity of this pyroptosis inducer to elicit hallmarks of immunogenic cell death. In addition, intratumoral injection of tigilanol tiglate can sensitize subcutaneous cancers to subsequent immune checkpoint inhibitors targeting CTLA-4 alone or in combination with PD-1.

查看原文本刊更多论文

惕各醇惕各酸酯的免疫溶瘤作用。

Tigilanol tiglate 是一种正在进行临床试验的溶瘤小分子。最近的一项研究揭示了这种热蛋白沉积诱导剂诱发免疫性细胞死亡的能力。此外，瘤内注射替吉兰醇替格酸酯可使皮下癌症对随后单独或与PD-1联合靶向CTLA-4的免疫检查点抑制剂敏感。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Oncoimmunology ONCOLOGYIMMUNOLOGY-IMMUNOLOGY

CiteScore

12.50

自引率

2.80%

发文量

276

审稿时长

24 weeks

期刊介绍： OncoImmunology is a dynamic, high-profile, open access journal that comprehensively covers tumor immunology and immunotherapy. As cancer immunotherapy advances, OncoImmunology is committed to publishing top-tier research encompassing all facets of basic and applied tumor immunology. The journal covers a wide range of topics, including: -Basic and translational studies in immunology of both solid and hematological malignancies -Inflammation, innate and acquired immune responses against cancer -Mechanisms of cancer immunoediting and immune evasion -Modern immunotherapies, including immunomodulators, immune checkpoint inhibitors, T-cell, NK-cell, and macrophage engagers, and CAR T cells -Immunological effects of conventional anticancer therapies.